Phase II Study of DCVAC/PCa Added After Radical Primary Prostatectomy for Patients With Localized Prostate Cancer

Inclusion Criteria: * Male 18 years and older * Histologically confirmed pT2 prostate cancer * Post radical prostatectomy * PSA values measured after the value greater than 0.020 ng/mL resulted in PSA doubling time (PSADT) equal or less than 12 months * Salvage radiotherapy naïve with PSA increase within 2 years or after salvage radiotherapy with PSA not higher than 1 ng/ml * Eastern Cooperative Oncology Group (ECOG) 0-2 Exclusion Criteria: * Confirmed brain and/or leptomeningeal metastases * Prior androgen deprivation therapy or orchiectomy for prostate cancer * Peripheral neuropathy of Common Toxicity Criteria (CTC) grade 2 or greater * Other uncontrolled intercurrent illness * Treatment with immunotherapy against prostate cancer * Clinically significant cardiovascular disease * Active autoimmune disease requiring treatment